Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2015. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in share interests.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the fair market value of an Ordinary Share at the point of exercise on May 14, 2015, which was £14.14.
Material Changes
The filing details a specific transaction involving Executive Director Sir Andrew Witty on May 14, 2015:
- Exercise of a nil-priced option over 57,932 shares and 7,821 shares granted on March 9, 2012.
- Both tranches vested on March 9, 2015, under the GSK Deferred Annual Bonus Plan.
- The company delivered the net-of-tax value in shares, totaling 34,849 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of a director's share transaction in accordance with paragraph 3.1.4R(1)(a) of the Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the share price of £14.14 on May 14, 2015, against market data.
- Confirm the vesting schedule and terms of the GSK Deferred Annual Bonus Plan for grants made in March 2012.
- Review the total shareholding of Sir Andrew Witty post-transaction to assess executive alignment.